CanaQuest Medical Corp Overview
Comprehensive Solution for Epilepsy Drug Commercialization and a
Platform for Future Neurological Treatments
CanaQuest is a clinical-stage life sciences company positioned to become the next “GW Pharma 2.0.” Guided by former GW Pharma executives Dr. Jordyn Stuart and Dr. Hunter Land—key figures behind the $7.2 billion acquisition of GW Pharma—CanaQuest is advancing CQ-001, a breakthrough therapy for refractory epilepsy. With clinical data from the Ontario Brain Institute demonstrating a 35% improvement in efficacy over current treatments, CQ-001 targets a patient population of 15 million. The company is pursuing FDA Orphan Drug Status, which would secure seven years of market exclusivity post-approval through late-stage Phase II trial.
Strategic & Regulatory Advantages
- Fast-Track Approval: Targeting FDA and Health Canada approvals within 3-4 years, leveraging Epidiolex’s regulatory precedent.
- Enhanced Formulation: CQ-001’s cannabidiol-based formula, combined with GRAS-certified EPA and DHA, optimizes efficacy while reducing side effects.
- Expanding Applications: Neurological disorders, mental health conditions, and veterinary medicine.
Leadership & Expertise
- Dr. Jordyn Stuart & Dr. Hunter Land – Key figures in Epidiolex’s commercialization and approvals.
- Dr. Paul Dick, DVM, MSc. – 30+ years in pharmaceutical and animal health industries.
- Eddie Francis, MS. – COO, molecular biology specialist.
- Neil Kothari, J.D. – Canadian corporate and securities lawyer, with experience in licensing and IP.
Market Opportunity
- Refractory Epilepsy Market: 30% of epilepsy patients lack effective treatment. Epidiolex’s 25% discontinuation rate underscores demand for safer alternatives. CQ-001 targets a $1.9B market
Breakthrough Pre-Clinical Findings
Western University trials confirm CQ-001’s unique mechanism:
- Neurostability & Cognitive Support: PPAR receptor activation reduces neuroinflammation and enhances cognition.
- Mental Health Applications: Modulates anxiety, PTSD, and mood disorders by balancing neurotransmitter pathways.
Clinical & Regulatory Acceleration – Collaboration
- NRC Canada – Human Health Therapeutics Research Centre to optimize drug dosing, predict
therapeutic outcomes,& study drug interactions in the brain, US $140K/project, 80% cost recovery
Audit Firm agreed to conduct a financial audit & defer fees until the Series A raise
Awards and Recognition
CanaQuest has been awarded, Medical Cannabinoid Development Company of the Year 2024 and Endocannabinoid Therapeutics Development Company of the Year 2024 by Global Health & Pharma, UK in its ninth annual Healthcare and Pharmaceutical Awards
Investment Opportunity
CanaQuest is advancing to the next phase of development with strong interest from a venture capital firm to participate in a syndicate of up to US$10 million. This funding will support clinical trials, expand into veterinary applications, and build strategic partnerships—contingent on securing a lead investor.
Funding Rounds & Expressions of Interest:
- Stage 1 – Seed Round (Next 6 Months)
- US$500K – Expression of interest from Portal Innovations, conditional upon a co-lead investor. Includes access to lab facilities and support infrastructure.
Stage 2 – Series A (Beginning Month 7) - US$10M – Committed interest from a VC firm to join a Series A syndicate focused on clinical trial advancement.
- US$1–2M – Second VC firm prepared to fund up to 35% of clinical trial costs, providing management expertise and operational support.
Call to Action:
We are currently raising a US$1M seed round to:
- Optimize drug dosing and interactions within the brain
- Strengthen and expand our intellectual property portfolio
- Initiate our IND (Investigational New Drug) application
We believe this will pave the way for a successful $30M Series A raise.
CanaQuest welcomes collaboration and strategic partnership opportunities
Contact: Paul Ramsay, CEO 416-704-3040 | paul@canaquest.com www.canaquest.com
Cautionary statement regarding forward-looking information:
This Overview contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on current expectations, estimates, forecasts, and projections about the industry in which CanaQuest Medical Corp operates and the beliefs and assumptions of the management of CanaQuest. Forward-looking statements may be identified by the use of forwardlooking terminology such as “plans,” “expects,” “believes,” “estimates,” “intends,” “may,” “will,” “should,” “could,” “anticipates,” “predicts,” “potential,” “continue,” or similar terms, variations of those terms or the negative of those terms. The forward-looking statements include but are not limited to, statements regarding:
- The anticipated benefits and effectiveness of Drug Candidate, CQ-001, and its potential to treat rare neurological conditions of epilepsy.
- The expected progress and outcomes of clinical trials for CQ-001 and the nutraceutical formulation, Mentanine™.
- CanaQuest’s ability to navigate the regulatory approval process successfully.
- The potential for commercialization of cannabidiol-based pharmaceuticals and nutraceuticals.
- The impact of the executive team appointments on CanaQuest’s clinical trials and regulatory approval processes.
These forward-looking statements are subject to a number of risks, uncertainties, and assumptions about CanaQuest Medical Corp, and there can be no assurance that the expectations of CanaQuest will be realized. Important factors that could cause actual results to differ materially from those in the forward-looking statements include:
- The possibility that clinical trials of CQ-001 may not be successful or may take longer than anticipated to complete.
- Challenges in securing regulatory approvals or changes in the regulatory environment.
- The potential for unforeseen side effects or other safety issues that could interrupt or halt clinical trials or affect patient enrollment.
- The ability to protect intellectual property and to operate without infringing upon the proprietary rights of others.
- Market acceptance of the Company’s products and competition from existing products or new products that may emerge.
- The impact of economic, competitive, governmental, technological, or other factors on the pharmaceutical and nutraceutical markets that could affect the Company’s operations or financial results.
- The company’s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated, and the results, cost, and timing of the company’s clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation, may not be as expected.
Investors are cautioned that any forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. CanaQuest Medical Corp undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
“The accompanying document is for informational purposes only and is not intended to be, and should not be construed as, an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any securities in CanaQuest Medical Corp. (the “Company”) or any related entity. This document does not constitute an offering memorandum, prospectus, or other offering document under applicable securities laws and is not intended to provide the basis for any investment decision. Any offer or sale of securities will be made only in compliance with applicable securities laws and will be subject to definitive documentation. None of the securities regulators or authorities in Canada or any other jurisdiction have reviewed or approved the contents of this document. No reliance should be placed on this document in making an investment decision. Recipients are encouraged to seek independent financial, legal, and tax advice before considering any potential investment in the Company”
Q2 2025